The trial will start in the next couple months, here's a link:
newscientist.com
Many question the 1 to 2% figure, or how it's to be interpreted. As I understand it, the condition our drug treats is a major portion of all people who are deaf, or have substantial hearing loss. It may be that in any given year treating more than 1 to 2% of the accrued population would be huge as that population is huge. I believe the benefits will be a much greater percentage, and those adding to the population each year may largely be benefited by the drug, rather than by getting hearing aids.
Personally, the chemo treatment I've been under for Acute Lymphoblastic Leukemia, and a related infection, has caused some hearing loss. It's unknown if it will be permanent, or not, but frankly at this time I can't worry about it. In the next few months I hope to be successful in stem cell transplantation, if that occurs, I can be concerned with it then. For now, I turn up the TV, and ask people to speak slightly louder.
Gary |
